INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit ...

When they opened me up they found a lot of disease in there,' says Anastacia. In fact, she had Crohn's disease, an inflammatory bowel condition that causes a range of distressing symptoms.

The company is also aiming for an upcoming Tremfya approval in Crohn’s disease, for which Stelara received an FDA nod in 2016. “I think there are a lot of patients in the immunology market ...

In addition to conventional treatments, some people may use complementary and alternative medicine (CAM) to help manage Crohn’s disease symptoms. This can include the use of essential oils.

moderate to severe active Crohn disease (CD), and moderate to severe active ulcerative colitis. A recent publication described in vitro pharmacology studies relevant to ustekinumab’s mechanism of ...

Janssen’s Stelara has gained FDA approval for use in patients with Crohn’s disease who have failed treatment or were intolerant to a TNF blocker drug. The monoclonal antibody drug targets ...